Bir Mobilya Fabrikasında Hücre Tasarımı ve Hücre Etkinliğinin Belirlenmesi

Günümüzde işletmeler artan rekabete uyum sağlayabilmek ve müşterilere daha hızlı cevap verebilmek için geleneksel üretim yöntemlerinin dışına çıkmak zorunda kalmaktadır. Üretkenliği arttırmak için benzer parça ve makinelerin bir araya getirilmesi felsefesine dayanan grup teknolojisi birçok işletme tarafından yaygın bir şekilde kullanılmaktadır. Hücresel imalat yaklaşımında, parçalar, tasarım ve imalat açısından benzerliklerine göre gruplandırılıp parça aileleri haline getirilirken, makineler ise iş akışına göre hücrelerde gruplandırılmaktadır. Böylece, hazırlık zamanları ve ara stoklardaki yığılmalar azalarak, üretim planlama ve çizelgelemede etkinlik artışı gözlenmektedir. Bu da üretimde verimliliği sağlar. Yapılan çalışmada, hat akışı üretim sistemine sahip olan bir mobilya fabrikasının taşımalardan kaynaklanan kayıplarını önlemek ve üretimde verimliliği artırmak amacıyla hücresel imalata geçiş için bir ön hazırlık yapılmıştır. Fabrikada makine grupları, parça aileleri ve hücre oluşum problemi üzerinde durulmuştur. Grup etkinliğini sağlamayı hedefleyen bir matematiksel model yardımıyla problem çözümlenmeye çalışılmıştır. Matematiksel model sonuçlarının mevcut durum ile karşılaştırılması yapılarak, firmaya önerilerde bulunulmuştur

The predictive value of the first trimester combined test for gestational diabetes mellitus

Objectives: To investigate the predictive importance of first trimester combined test markers pregnancy-associated plasma protein-A (PAPP-A), human chorionic gonadotropin β (β-hCG) and nuchal translucency (NT) for gestational diabetes mellitus (GDM).   Material and methods: Pregnant women which both first trimester combined test and GDM screening were performed during antenatal follow-up were included in this retrospective case-control study. The cases were divided into two groups as GDM screening positive and negative. Demographic, clinical and laboratory data of both groups were compared. Predictive tests were applied to the first trimester combined test data for the detection of GDM. Results: A total of 378 patients, 171 (45.2%) in the control group and 207 (54.8%) in the GDM group. The age (control:30.9 ± 5.2; GDM:30.5 ± 5.1; p = 0.844) and NT (control:1.254 ± 0.289; GDM:1.319 ± 0.299; p = 0.074) data of the groups were statistically similar. MoM PAPP-A (GDM:0.967 ± 0.685; control:1.191 ± 0.624; p < 0.001) and MoM f-βhCG (GDM:0.9 ± 0.602; control:1.103 ± 0.746; p = 0.001) levels of the GDM group were lower than the control group. In the binary logistic regression model, MoM PAPP-A and MoM f-βhCG variables were found to be effective on GDM. In the ROC analysis of these variables, the MoM PAPP-A (0.654) had the highest area under the curve. According to the optimum cut-off point (≤ 0.885) of the MoM PAPP-A, we found a sensitivity of 66.7% and a specificity of 65.50% for predicting GDM. Conclusions: Our study showed that serum PAPP-A and f-βhCG MoM values, which are among the first trimester combined test parameters, can be used in the early pregnancy period for the prediction of GDM

Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5±4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of ?50x109/L was 11.6±8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8±9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients.Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency

Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children

Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3\% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7\%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency